Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
- PMID: 28683818
- PMCID: PMC5501520
- DOI: 10.1186/s40168-017-0286-2
Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
Abstract
Background: Effective treatment of Mycobacterium tuberculosis (Mtb) infection requires at least 6 months of daily therapy with multiple orally administered antibiotics. Although this drug regimen is administered annually to millions worldwide, the impact of such intensive antimicrobial treatment on the host microbiome has never been formally investigated. Here, we characterized the longitudinal outcome of conventional isoniazid-rifampin-pyrazinamide (HRZ) TB drug administration on the diversity and composition of the intestinal microbiota in Mtb-infected mice by means of 16S rRNA sequencing. We also investigated the effects of each of the individual antibiotics alone and in different combinations.
Results: While inducing only a transient decrease in microbial diversity, HRZ treatment triggered a marked, immediate and reproducible alteration in community structure that persisted for the entire course of therapy and for at least 3 months following its cessation. Members of order Clostridiales were among the taxa that decreased in relative frequencies during treatment and family Porphyromonadaceae significantly increased post treatment. Experiments comparing monotherapy and different combination therapies identified rifampin as the major driver of the observed alterations induced by the HRZ cocktail but also revealed unexpected effects of isoniazid and pyrazinamide in certain drug pairings.
Conclusions: This report provides the first detailed analysis of the longitudinal changes in the intestinal microbiota due to anti-tuberculosis therapy. Importantly, many of the affected taxa have been previously shown in other systems to be associated with modifications in immunologic function. Together, our findings reveal that the antibiotics used in conventional TB treatment induce a distinct and long lasting dysbiosis. In addition, they establish a murine model for studying the potential impact of this dysbiosis on host resistance and physiology.
Keywords: 16S rRNA; Antibiotics; Dysbiosis; Microbiota; Tuberculosis.
Figures






Similar articles
-
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability.mBio. 2023 Apr 25;14(2):e0035323. doi: 10.1128/mbio.00353-23. Epub 2023 Mar 6. mBio. 2023. PMID: 36877010 Free PMC article.
-
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):707-12. doi: 10.1164/ajrccm/143.4_Pt_1.707. Am Rev Respir Dis. 1991. PMID: 1901200 Clinical Trial.
-
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445. JAMA. 2000. PMID: 10732934 Clinical Trial.
-
Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.Expert Opin Drug Saf. 2004 May;3(3):187-98. doi: 10.1517/eods.3.3.187.31073. Expert Opin Drug Saf. 2004. PMID: 15155147 Review.
-
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].Kekkaku. 2001 Jan;76(1):33-43. Kekkaku. 2001. PMID: 11211781 Review. Japanese.
Cited by
-
Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis.Nat Commun. 2021 Feb 18;12(1):1141. doi: 10.1038/s41467-021-21475-y. Nat Commun. 2021. PMID: 33602926 Free PMC article.
-
Characterization of gut microbiota in children with pulmonary tuberculosis.BMC Pediatr. 2019 Nov 18;19(1):445. doi: 10.1186/s12887-019-1782-2. BMC Pediatr. 2019. PMID: 31735171 Free PMC article.
-
PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques.Sci Immunol. 2021 Jan 15;6(55):eabf3861. doi: 10.1126/sciimmunol.abf3861. Sci Immunol. 2021. PMID: 33452107 Free PMC article.
-
Microbiome-immune interactions in tuberculosis.PLoS Pathog. 2021 Apr 15;17(4):e1009377. doi: 10.1371/journal.ppat.1009377. eCollection 2021 Apr. PLoS Pathog. 2021. PMID: 33857251 Free PMC article. Review.
-
Impact on the Gut Microbiota of Intensive and Prolonged Antimicrobial Therapy in Patients With Bone and Joint Infection.Front Med (Lausanne). 2021 Mar 5;8:586875. doi: 10.3389/fmed.2021.586875. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33748154 Free PMC article.
References
-
- WHO . Global tuberculosis report. 2016. Geneva: WHO; 2016.
-
- Brennan PJ, Young DB. Isoniazid. Tuberculosis (Edinb). 2008;88(2):112–116. - PubMed
-
- Brennan PJ, Young DB. Pyrazinamide. Tuberculosis (Edinb). 2008;88(2):141–144. - PubMed
-
- Brennan PJ, Young DB. Rifampin. Tuberculosis (Edinb). 2008;88(2):151–154. - PubMed
-
- Brennan PJ, Young DB. Ethambutol. Tuberculosis (Edinb). 2008;88(2):102–105. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources